Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection.
We studied 14 patients acutely infected with wild-type HIV, who underwent supervised treatment interruptions after initial antiretroviral treatment including lamivudine. Lamivudine resistance mutations emerged for the first time during supervised treatment interruptions in one patient. Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted.
Tremblay
Cecile L
CL
Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hicks
Jennifer L
JL
Sutton
Lorraine
L
Giguel
Francoise
F
Flynn
Theresa
T
Johnston
Mary
M
Sax
Paul E
PE
Walker
Bruce D
BD
Hirsch
Martin S
MS
Rosenberg
Eric S
ES
D'Aquila
Richard T
RT
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D024882:Drug Resistance, Viral / Q000235:genetics*; D015751:Genes, pol / Q000235:genetics*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D009154:Mutation / Q000235:genetics*; D012367:RNA, Viral / Q000097:blood
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019259:Lamivudine